Mechanism identified for drug resistance in glioblastoma

Phase I study of CAR T-cell therapy shows clinical activity in glioblastoma

A phase I CAR T-cell therapy trial for the treatment of glioblastoma demonstrated promising clinical activity, according to research published in Nature Medicine.

March 15, 2024

Vol.50 No.11

Clinical Roundup

AI harnesses tumor genetics to predict treatment response

Scientists at University of California San Diego School of Medicine used a machine learning algorithm to predict when cancer will resist chemotherapy.

January 19, 2024

Vol.50 No.03

Clinical Roundup

Epigenomic platform may predict NSCLC immunotherapy response using liquid biopsies

Data published in The Journal for ImmunoTherapy of Cancer show ClearNote Health’s epigenomic platform may provide a novel tissue-free, liquid biopsy-based approach for prediction and monitoring of immunotherapy response for non-small cell lung cancer patients.

January 19, 2024

Vol.50 No.03

Clinical Roundup

Sylvester study shows glioblastoma can mimic healthy neurons

A study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into glioblastoma neuron mimicry and potential therapies to prevent treatment resistance.

January 19, 2024

Vol.50 No.03

Funding Opportunities

TGen establishes fellowship program in GBM

The Translational Genomics Research Institute, part of City of Hope, established a fellowship in glioblastoma multiforme research. The Lori Lane/Andrew Spyrow Fellowship honors the lives of Lori Lane and Andrew Spyrow who fought GBM bravely, teaching all of us to experience the joy of life and dedicating their journey to the advancement of treatment improving the quality and longevity of life for those facing this devastating cancer.

December 01, 2023

Vol.49 No.44

Letter To The Editor

“Field of Dread” (continued): Do “forever chemicals” in AstroTurf cause GBM?

A letter to the editor by The Philadelphia Inquirer’s James Neff raises concerns about conflicts of interest in a recent Guest Editorial published in The Cancer Letter. The authors and The Cancer Letter editor respond.

October 27, 2023

Vol.49 No.40

Mechanism identified for drug resistance in glioblastoma

YOU MAY BE INTERESTED IN

Phase I study of CAR T-cell therapy shows clinical activity in glioblastoma

AI harnesses tumor genetics to predict treatment response

Epigenomic platform may predict NSCLC immunotherapy response using liquid biopsies

Sylvester study shows glioblastoma can mimic healthy neurons

TGen establishes fellowship program in GBM

“Field of Dread” (continued): Do “forever chemicals” in AstroTurf cause GBM?

Renew today!

Subscriber content

Login